



# STATE OF IOWA

CHESTER J. CULVER, GOVERNOR  
PATTY JUDGE, LT. GOVERNOR

DEPARTMENT OF HUMAN SERVICES  
KEVIN W. CONCANNON, DIRECTOR

## Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting August 6, 2008

**Location: Iowa Medicaid Enterprise  
100 Army Post Rd.  
Des Moines, Iowa 50315**

**Time: 9:30 a.m. – 1:30 p.m.**

### Final Agenda

1. Welcome & Introductions
  - a) Commission Members and Staff
  - b) Approval of the minutes
2. Case Reviews
3. Management Reports
4. ProDUR Edits
  - a) Pristiq™ - P&T Recommendation to consider 30/30 quantity limit on both strengths
5. Focus Studies
  - a) Underutilization of Inhaled Corticosteroids – Follow up
  - b) Concurrent Benzodiazepine & Sedative Hypnotics – Follow up
  - c) Chronic Triptan Use without Migraine Prophylaxis – Proposed; presentation of preliminary data
  - d) Chronic Lidoderm Patch Use – Proposed; presentation of preliminary data
  - e) Quarterly Narcotic Utilization Report – Proposed; discussion
  - f) Commission Member Interests on future Focus Studies
6. Public Comment
7. Direction of DUR
  - a) Time of Meeting – Current time working best for Members?
  - b) Capabilities of Data – Discussion
  - c) Presentation of Member Profiles – Feedback from Members
  - d) Management Reports – Feedback from Members
  - e) Public Comment Policy – Review of current policy
8. Prior Authorization
  - a) Vusion Ointment – Proposed Clinical PA Criteria
  - b) Annual Review of Clinical PA Criteria – Recommended Categories for Review

9. Public Comment
10. Strategies, Challenges, and Initiatives
  - a) Metabolic Testing in Members on Atypical Antipsychotics
11. Miscellaneous
  - a) DUR Digest – 2008 Vol. 20 No. 3; Article Suggestions
  - b) MedWatch
12. Executive Closed Session
  - a) Approval of Minutes
  - b) Member Profiles
13. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. This public comment period shall last no more than 15 minutes. Individuals may respectfully offer comments, with priority being given to current Commission meeting agenda items.

**[www.iadur.org](http://www.iadur.org)**

For more information contact the DUR Director, Chad Bissell, R.Ph., Pharm.D. at [cbissell@ghsinc.com](mailto:cbissell@ghsinc.com) or (515) 725-1271